Small-molecule disruption of androgen receptor-dependent chromatin clusters

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) is driven by sustained androgen receptor (AR) signaling.
• Current AR antagonists like enzalutamide are often ineffective in mCRPC with high AR expression.

Purpose of the Study:

• To develop novel AR antagonists effective against AR-overexpressing mCRPC.
• To investigate the molecular mechanisms underlying the action of these new agents.

Main Methods:

• Screening and characterization of novel AR antagonists (BG-15a/n).
• In vitro and in vivo studies using mCRPC models with AR overexpression.
• Analysis of AR localization, AR-target gene expression, and chromatin structure changes.

Main Results:

• BG-15a/n bind to the AR ligand-binding domain and promote nuclear localization.
• These agents potently down-regulate AR-target genes and inhibit cell/tumor growth in mCRPC models.
• Treatment disrupts enhancer-promoter chromatin loops crucial for AR-driven gene expression.

Conclusions:

• BG-15a/n demonstrate efficacy in preclinical models of relapsed AR-driven mCRPC.
• These compounds offer a potential new therapeutic strategy for mCRPC patients with high AR expression.
• The mechanism involves disruption of AR-mediated epigenetic regulation via chromatin loop collapse.